7.4 Stress Hyperglycemia, Intensive Insulin Protocols, and Adrenal / Thyroid Axis Dysregulation

7.4 Stress Hyperglycemia, Intensive Insulin Protocols, and Adrenal / Thyroid Axis Dysregulation

Core Knowledge: Severe thermal trauma profoundly disrupts systemic endocrine homeostasis, precipitating severe stress-induced hyperglycemia, peripheral insulin resistance, adrenal axis exhaustion, and altered thyroid hormone metabolism. Even in patients without pre-existing diabetes, circulating glucose levels frequently surge above $250\text{ to }300\text{ mg/dL}$. Uncontrolled hyperglycemia suppresses immune defense, degrades newly grafted tissue, and triggers osmotic diuresis—a deceptive phenomenon that can mislead fluid resuscitation. Certified Burn Registered Nurses (CBRN) must master protocolized continuous intravenous insulin therapy, recognize endocrine failure states such as CIRCI, and avoid unnecessary hormonal interventions in Euthyroid Sick Syndrome.

---

1. Pathophysiology of Burn-Induced Stress Hyperglycemia

Stress hyperglycemia in severe burns is not simply a relative insulin deficiency; it is a complex metabolic derangement characterized by accelerated endogenous glucose output combined with massive peripheral insulin resistance.

                  DUAL PATHWAY OF POST-BURN STRESS HYPERGLYCEMIA
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │               Thermal Injury (≥20–40% TBSA) & Systemic SIRS                 │
  └──────────────────────────────────────┬──────────────────────────────────────┘
                                         │
         ┌───────────────────────────────┴───────────────────────────────┐
         ▼                                                               ▼
  ┌──────────────────────────────┐                              ┌──────────────────────────────┐
  │  UNCHECKED HEPATIC GLUCOSE   │                              │     PERIPHERAL SKELETAL      │
  │          PRODUCTION          │                              │      INSULIN RESISTANCE      │
  ├──────────────────────────────┤                              ├──────────────────────────────┤
  │ • Catecholamines & Cortisol  │                              │ • TNF-α, IL-6 & circulating  │
  │   drive glycogenolysis       │                              │   FFAs induce serine         │
  │ • Glucagon stimulates        │                              │   phosphorylation of IRS-1   │
  │   gluconeogenesis            │                              │ • Impaired intracellular     │
  │ • Liver remains refractory to│                              │   translocation of GLUT4     │
  │   normal insulin feedback    │                              │   vesicles to cell membrane  │
  │   suppression                │                              │ • Skeletal muscle cannot     │
  │                              │                              │   import circulating glucose │
  └──────────────┬───────────────┘                              └──────────────┬───────────────┘
                 │                                                             │
                 └───────────────────────────────┬─────────────────────────────┘
                                                 │
                                                 ▼
                                  ┌──────────────────────────────┐
                                  │    SEVERE HYPERGLYCEMIA      │
                                  │    (Blood Glucose >180–300)  │
                                  └──────────────────────────────┘

Molecular Mechanisms:

1. Hepatic Gluconeogenesis Surge: The liver increases glucose production up to 200% to 300% of normal, driven by the continuous supply of gluconeogenic precursors (alanine, glutamine, lactate, and glycerol) and high glucagon-to-insulin ratios.
2. Post-Receptor GLUT4 Defect: Circulating pro-inflammatory cytokines (especially TNF-$\alpha$ and IL-6) and high levels of intracellular free fatty acids phosphorylate the Insulin Receptor Substrate-1 (IRS-1) on serine residues rather than tyrosine residues. This halts downstream PI3K/Akt signaling, preventing the translocation of Glucose Transporter 4 (GLUT4) vesicles to the sarcolemma in skeletal muscle.

---

2. Clinical Consequences of Glucose Toxicity in Burns

Maintaining glycemic control is essential to prevent systemic failure:

                        HAZARDS OF UNCONTROLLED HYPERGLYCEMIA
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ 1. IMMUNE DEFENSE IMPAIRMENT:                                               │
  │    • Inhibits neutrophil chemotaxis, phagocytosis, and oxidative burst.     │
  │    • Increases incidence of bacteremia, pneumonia, and invasive wound sepsis│
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ 2. OSMOTIC DIURESIS & RESUSCITATION DECEPTION:                              │
  │    • Blood glucose >180 mg/dL exceeds renal tubular reabsorption capacity.  │
  │    • Glycosuria pulls water into urine, falsely elevating hourly urine      │
  │      output (UOP) despite ongoing severe intravascular hypovolemia!         │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ 3. GRAFT FAILURE & POOR WOUND REPAIR:                                       │
  │    • Endothelial dysfunction and non-enzymatic glycation of tissue proteins.│
  │    • Impairs fibroblast proliferation and halts split-thickness graft take. │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ 4. ACCELERATED MUSCLE CATABOLISM & MORTALITY:                               │
  │    • Induces mitochondrial dysfunction, increases apoptosis, and worsens    │
  │      hyperosmolar stress and multi-organ failure.                           │
  └─────────────────────────────────────────────────────────────────────────────┘

[!CRITICAL] Resuscitation Deception Alert: When a burn patient's blood glucose exceeds $\approx 180\text{ mg/dL}$, glucose spills into the renal tubules, producing an osmotic diuresis. An inexperienced clinician seeing a urine output of $1.5\text{ mL/kg/hr}$ might inappropriately decrease fluid resuscitation rates. In reality, the patient is losing volume to osmotic diuresis while their intravascular compartment remains severely hypoperfused. Always check urine for glucose and verify blood glucose levels when interpreting urine output!

---

3. Glycemic Targets and Continuous IV Insulin Protocols

Evolution of Evidence-Based Glycemic Targets

• Historical Tight Control (80–110 mg/dL): Popularized by early single-center trials, this approach was conclusively refuted by the multicenter NICE-SUGAR trial, which demonstrated that ultra-tight control resulted in unacceptable rates of fatal hypoglycemia and increased mortality.
• American Burn Association (ABA) Target Corridor: 130 to 180 mg/dL (7.2 to 10.0 mmol/L).
• This range captures the anabolic, anti-inflammatory, and wound-healing benefits of insulin therapy while providing a safe buffer against clinical hypoglycemia.

                       GLYCEMIC CONTROL TARGET CORRIDORS
  Blood Glucose (mg/dL)
   300 ┼────────────────────────────────────────────────────────── Severely Elevated
   250 ┼
   200 ┼
   180 ┼────────────────────────────────────────────────────────── Upper Target Limit
       │           OPTIMAL ABA TARGET CORRIDOR (130–180 mg/dL)
   130 ┼────────────────────────────────────────────────────────── Lower Target Limit
   110 ┼
    70 ┼────────────────────────────────────────────────────────── Hypoglycemia Threshold
    40 ┼────────────────────────────────────────────────────────── Severe / Neuroglycopenia

Continuous IV Regular Insulin Infusion Principles

1. Route of Administration: Continuous IV infusion is mandatory. Subcutaneous injections (e.g., glargine, lispro) are contraindicated in acute burns due to erratic, unpredictable absorption across edematous subcutaneous tissues.
2. Dynamic Protocol Titration: Regular insulin is infused via a dedicated IV line, titrated hourly based on point-of-care (POC) blood glucose or arterial line blood gas measurements.
3. Anabolic Action of Insulin: Beyond glucose lowering, exogenous insulin acts as an anabolic hormone in burns—stimulating skeletal muscle amino acid uptake, suppressing proteolysis, and promoting hepatic protein synthesis.

Nursing Management of Hypoglycemia

• Threshold: Blood glucose $<70\text{ mg/dL}$ (severe $<40\text{ mg/dL}$).
• Immediate Protocol Action:
  1. Stop the continuous IV regular insulin infusion immediately.
  2. Administer 25 to 50 mL of 50% Dextrose (D50W) IV push (12.5 to 25 g dextrose).
  3. Recheck blood glucose every 15 minutes until blood glucose is $\ge 100\text{ mg/dL}$.
  4. The Enteral Feed Rule: If enteral nutrition or TPN is paused for any reason (e.g., extubation, bedside wound debridement, or operating room transport), the nurse must immediately decrease the insulin infusion rate or start a concurrent infusion of 10% Dextrose in Water (D10W) at the same hourly rate to prevent sudden, catastrophic hypoglycemia.

---

4. Endocrine Axis Alterations in Major Thermal Injury

Severe burns induce dramatic secondary disturbances across the adrenal and thyroid axes that require discerning clinical management.

                    ENDOCRINE AXIS DISTURBANCES IN SEVERE BURNS
  ┌────────────────────────────────────────┬────────────────────────────────────────┐
  │       ADRENAL AXIS DYSFUNCTION         │       THYROID AXIS DYSFUNCTION         │
  │               (CIRCI)                  │       (Euthyroid Sick Syndrome)        │
  ├────────────────────────────────────────┼────────────────────────────────────────┤
  │ • Initial Stage: Extreme high cortisol │ • Hormone Profile: Low T3, low/normal  │
  │ • Late Stage: Adrenal exhaustion and   │   T4, normal/low TSH, high reverse T3  │
  │   tissue corticosteroid resistance     │ • Mechanism: Downregulation of         │
  │ • Clinical Sign: Vasopressor-refractory│   peripheral 5'-deiodinase by cytokines│
  │   hypotension in septic shock          │ • Clinical Meaning: Evolutionary       │
  │ • Diagnosis: Random total cortisol     │   adaptive hypometabolism to save LBM  │
  │   <10 mcg/dL or delta <9 mcg/dL after  │ • Treatment: DO NOT ADMINISTER THYROID │
  │   cosyntropin stimulation              │   HORMONE REPLACEMENT; therapy worsens │
  │ • Treatment: Stress-dose Hydrocortisone│   protein wasting and cardiac strain   │
  │   (200–300 mg/day IV divided/drip)     │                                        │
  └────────────────────────────────────────┴────────────────────────────────────────┘

1. Critical Illness-Related Corticosteroid Insufficiency (CIRCI)

• Following the initial hypercortisolemic surge, prolonged critical illness and endotoxemia can impair adrenal steroidogenesis and downregulate glucocorticoid receptors.
• Presentation: Suspected in burn patients with septic shock who remain persistently hypotensive (MAP $<65\text{ mmHg}$) despite aggressive fluid resuscitation and escalating high-dose vasopressor support (norepinephrine $>0.25\text{ mcg/kg/min}$ plus vasopressin).
• Management: Administer stress-dose Hydrocortisone 50 mg IV every 6 hours (or 200 mg/day continuous IV infusion) until shock resolves, followed by a gradual taper.

2. Euthyroid Sick Syndrome (Non-Thyroidal Illness Syndrome)

• Burn cytokines (IL-6, TNF-$\alpha$) and high cortisol inhibit hepatic 5'-deiodinase, blunting the peripheral conversion of thyroxine ($T_4$) into active triiodothyronine ($T_3$), shunting metabolism toward inactive reverse $T_3$ ($rT_3$).
• Clinical Rule: This represents a protective, energy-conserving physiologic adaptation. Administering levothyroxine ($T_4$) or liothyronine ($T_3$) is strictly contraindicated because it accelerates skeletal muscle proteolysis, exacerbates hypermetabolism, and increases mortality.